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Abstract. Twenty-six benzocycloheptoxazine derivatives were
investigated for their tumor-specific cytotoxicity and apoptosis-
inducing activity against three human normal cells (gingival
fibroblast HGF, pulp cell HPC, periodontal ligament fibroblast
HPLF) and four human tumor cell lines (squamous cell
carcinoma HSC-2, HSC-3, HSC-4, promyelocytic leukemia
HL-60). Benzo[b]cyclohepta[e][1,4]thiazine [1] exhibited very
weak cytotoxicity, whereas its 6,8,10-tribromo derivative [3]
exhibited higher cytotoxicity and tumor specificity (TS=5.6).
6H-Benzo[b]cyclohepta[e][1,4]diazine [4] and its cation [5]
exhibited no tumor specificity. Among eighteen
benzo[b]cyclohepta[e][1,4]oxazine derivatives [6-23], 6,8,10-
triboromo- [9], 6-bromo-2-methyl- [20], and 6-bromo-2-
chloro- [21] derivatives showed the highest tumor-specific
cytotoxicity (TS=12.5, 9.1 and 11.5, respectively). 14H-
[1,4]Benzoxazino[3',2':3,4]cyclohepta[1,2-b][1,4]benzoxazine
[24] and its 7-bromo- [25] and 7-isopropyl- [26] derivatives
had much lower cytotoxicity and tumor-specificity. Compounds
[9, 20, 21] at 50% cytotoxic concentration (CC50) induced
internucleosomal DNA fragmentation and caspase activation
in HL-60 cells. On the other hand, these compounds induced
apoptosis only at concentrations higher than CC50 in HSC-2
cells and failed to induce apoptosis in HSC-4 cells. Compounds
[9, 20, 21] induced the formation of acidic organelles as
measured by acridine orange staining. Transmission electron
microscopy demonstrated the induction of moderate
enlargement of mitochondria, the endoplasmic reticulum and
nuclear membrane, and the vacuolation of the endoplasmic
reticulum and the presence of a number of lamellar body-like
organelles. These results indicate the diversity of the type of cell
death induced by benzocycloheptoxazine derivatives in human
tumor cell lines.
Hinokitiol and related compounds with a tropolone skeleton
(1-3) have been reported to exhibit various biological
activities such as antimicrobial (4), antifungal (5), and
phytogrowth-inhibitory activities (6, 7), cytotoxic effects on
mammalian tumor cells (8, 9), and inhibitory effects on
catechol-O-methyltransferase (10) and metalloproteases (4).
Hinokitiol acetate did not exhibit cytotoxic activity (9),
antimicrobial activity or metalloprotease inhibition (4),
suggesting that these biological effects of hinokitiol-related
compounds may result from the metal chelation between the
carbonyl group at C-1 and the hydroxyl group at C-2 in the
tropolone skeleton. Tropolone derivatives with a phenolic
OH group, hinokithiol, its tosylate and methyl ethers have
exhibited higher tumor-specific cytotoxic activity, while 2-
aminotropolone showed the highest tumor-specificity and
induced apoptosis in the human promyelocytic leukemic HL-
60 cell line, possibly by radical-mediated redox reaction (11).
2,4-Dibromo-7-methoxytropone inhibited nitric oxide
production by lipopolysaccharide (LPS)-stimulated mouse
macrophage-like cells via the inhibition of inducible nitric
oxide synthase (iNOS) expression, rather than via the
radical-mediated mechanism (12).
Differing from common, unreactive heterocyclic-annulated
tropylium compounds, cyclohepta[b][1,4]benzoxazines and
their S- and O-analogues are usually very reactive, especially
towards 1,4-difunctional nucleophiles such as O-
phenylenediamine, ethylenediamine and their S- and O-
analogues (13). We therefore investigated here 26
benzocycloheptoxazines derivatives (Figure 1) for their tumor-
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specific cytotoxicity and apoptosis-inducing activity against
three normal human cells [gingival fibroblast (HGF), pulp cell
(HPC), periodontal ligament fibroblast (HPLF)] and four
human tumor cell lines (oral squamous cell carcinoma HSC-2,
HSC-3, HSC-4; promyelocytic leukemia HL-60).
Materials and Methods
Materials. The following chemicals and reagents were obtained
from the companies indicated: Dulbecco's modified Eagle’s
medium (DMEM; Gibco BRL, Grand Island, NY, USA); fetal
bovine serum (FBS; JRH, Bioscience, Lenexa, KS, USA); dimethyl
sulfoxide (DMSO; Wako Pure Chem, Ind, Ltd, Osaka, Japan);
RPMI-1640 and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT; Sigma Chem Co., St. Louis, MO, USA).
Synthesis of benzocycloheptoxazines. Benzocycloheptoxazine
derivatives were synthesized according to methods previously
published (Table I).
Cell culture. Three human oral tumor cell lines (HSC-2, HSC-3,
HSC-4) and three normal human cells (HGF, HPC, HPLF) were
cultured in DMEM supplemented with 10% heat-inactivated FBS.
Human promyelocytic leukemic HL-60 cells were cultured in
RPMI 1640 supplemented with 10% heat-inactivated FBS. Tumor
cell lines were obtained from Riken Cell Bank Japan. Normal cells
were prepared from periodontal tissues, according to the guideline
of the Institutional Board of Meikai University Ethics Committee
(No. 0707) after obtaining informed consent from the patients.
Since HGF, HPC and HPLF cells have a limited lifespan due to in
vitro senescence (31), these cells were used for the present study at
a population doubling level of 5-8.
Assay for cytotoxic activity. Cells (other than HL-60 cells) were
inoculated at 5x103 cells/well in 96-microwell plates (Becton
Dickinson Labware, NJ, USA), unless otherwise stated. After 48
hours, the medium was removed by suction with an aspirator and
replaced with 0.1 mL of fresh medium containing different
concentrations of the test compounds. Each test compound was
dissolved in DMSO at a concentration of 50 mM. The first well
contained 500 µ M sample and was then diluted 2-fold sequentially,
with 3 replicate wells for each concentration. Cells were incubated
for another 24 hours and the relative viable cell number was then
determined by the MTT method. In brief, cells were washed with
phosphate-buffered saline without calcium and magnesium
(PBS(–)) which was replaced with fresh culture medium containing
0.2 mg/mL MTT and cells were incubated for another 4 hours. The
cells were lysed with 0.1 mL of DMSO and the absorbance of the
cell lysate at 540 nm A540 was determined using a microplate
reader (Biochromatic Labsystem, Helsinki, Finland) (32). The A540
of control cells was usually in the range from 0.40 to 0.90.
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Table I. Benzocycloheptoxazine derivatives synthesized in this study.
Compound Name Method used
number (Reference)
[1] benzo[b]cyclohepta[e][1,4]thiazine 14-18
[2] 6,8-dibromobenzo[b]cyclohepta[e][1,4]thiazine 14, 15, 17
[3] 6,8,10-tribromobenzo[b]cyclohepta[e][1,4]thiazine 14, 15, 17
[4] 6H-benzo[b]cyclohepta[e][1,4]diazine 17-19
[5] 6H-benzo[b]cyclohepta[e][1,4]diazine cation 17-19
[6] benzo[b]cyclohepta[e][1,4]oxazine 20-22
[7] 6-bromobenzo[b]cyclohepta[e][1,4]oxazine 23-27
[8] 6,8-dibromobenzo[b]cyclohepta[e][1,4]oxazine 26, 28-30
[9] 6,8,10-tribromobenzo[b]cyclohepta[e][1,4]oxazine 26, 28-30
[10] 8-bromobenzo[b]cyclohepta[e][1,4]oxazine 26, 28-30
[11] 7-bromobenzo[b]cyclohepta[e][1,4]oxazine 22, 30
[12] 9-bromobenzo[b]cyclohepta[e][1,4]oxazine 22, 30
[13] 8-isopropylbenzo[b]cyclohepta[e][1,4]oxazine 21, 22
[14] 9-isopropylbenzo[b]cyclohepta[e][1,4]oxazine 21, 22




[19] 2-methylbenzo[b]cyclohepta[e][1,4]oxazine 22, 25
[20] 6-bromo-2-methylbenzo[b]cyclohepta[e][1,4]oxazine 22, 25
[21] 6-bromo-2-chlorobenzo[b]cyclohepta[e][1,4]oxazine 22, 25
[22] 8-bromo-2-methylbenzo[b]cyclohepta[e][1,4]oxazine 22, 28
[23] 8-bromo-2-chlorobenzo[b]cyclohepta[e][1,4]oxazine 22, 28
[24] 14H-[1,4]benzoxazino[3’,2’:3,4]cyclohepta[1,2-b][1,4]benzoxazine 22-25, 27
[25] 14H-7-bromo[1,4]benzoxazino[3’,2’:3,4]cyclohepta[1,2-b][1,4]benzoxazine 28, 29
[26] 14H-7-isopropyl[1,4]benzoxazino[3’,2’:3,4]cyclohepta[1,2-b][1,4]benzoxazine 22, 29
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Table II. Cytotoxic activity of benzocycloheptoxazines against human normal and tumor cells.
Cytotoxic activity (CC50: M)
Normal human cells Human tumor cell lines
Compound MW HGF HPC HPLF HSC-2 HSC-3 HSC-4 HL-60 TS
[1] 211.1 >500.0 >500.0 499.6 486.1 449.2 >500.0 149.1 1.3
[2] 369 23.2 77.2 24.4 87.9 51.5 60.2 9.6 0.8
[3] 448 63.9 87.2 95.2 11.1 13.5 18.5 15.1 5.6
[4] 194 73.6 84.2 177.6 25.3 36.8 46.7 13.7 3.7
[5] 254 >500.0 >500.0 >500.0 >500.0 449.3 >500.0 406.2 1.1
[6] 195 349.0 369.7 379.8 264.5 202.3 328.8 42.7 1.7
[7] 273.9 74.8 97.4 106.9 37.2 16.3 75.6 12.7 2.6
[8] 352.8 451.3 397.2 414.0 267.4 165.6 319.7 231.4 1.7
[9] 431.7 406.9 383.6 >500.0 28.6 47.0 34.8 27.4 12.5
[10] 273.9 278.1 310.8 176.0 90.0 90.0 142.2 34.5 2.9
[11] 273.9 126.7 128.9 190.4 83.3 57.2 123.2 10.7 2.2
[12] 273.9 71.2 69.2 156.1 71.8 53.7 91.9 36.9 1.6
[13] 236 298.1 263.1 310.9 51.3 38.3 79.4 18.0 6.2
[14] 236 173.7 273.1 232.4 109.2 70.9 158.5 27.8 2.5
[15] 253 301.1 360.0 376.7 84.0 63.1 174.1 22.4 4
[16] 253 11.3 41.1 39.3 18.9 15.2 25.6 6.6 1.8
[17] 331.9 356.3 144.4 179.9 57.1 43.4 84.5 11.0 4.6
[18] 253 >500.0 >500.0 >500.0 209.6 140.8 352.5 58.3 2.6
[19] 209 157.1 230.1 186.1 91.9 65.9 134.7 19.8 2.4
[20] 287.9 167.7 103.1 149.9 16.4 13.3 26.0 6.1 9.1
[21] 308.4 124.9 358.6 449.6 25.2 21.5 47.9 13.8 11.5
[22] 287.9 136.4 338.8 284.4 100.0 62.0 179.8 141.0 2.1
[23] 308.4 346.7 366.6 418.6 72.1 60.4 236.8 20.8 3.9
[24] 300 >500.0 >500.0 >500.0 >500.0 442.8 >500.0 326.4 1.1
[25] 378.9 >500.0 >500.0 >500.0 444.5 344.0 430.5 67.6 1.6
[26] 342 >500.0 >500.0 >500.0 >500.0 450.3 >500.0 148.2 1.3
Each value represents the mean from three independent experiments.
HL-60 cells were inoculated at 7.5x104 cells/0.1 mL in 96-
microwell plates and different concentrations of test compounds
were added. After incubation for 48 hours, the viable cell number
was determined by trypan blue exclusion under a light microscope.
The 50% cytotoxic concentration (CC50) was determined from
the dose response curve. Tumor-specificity (TS) was determined by
the following equation:
TS={[CC50 (HGF) + CC50 (HPC) + CC50 (HPLF)] / [CC50 (HSC-2)
+ CC50 (HSC-3) + CC50 (HSC-4) + CC50 (HL-60)]} x (4/3).
Assay for DNA fragmentation. Cells were washed once with PBS(–)
and lysed with 50 µ L lysate buffer [50 mM Tris-HCl (pH 7.8),
10 mM EDTA, 0.5% (w/v) sodium N-lauroyl-sarcosinate solution].
The solution was incubated with 0.4 mg/mL RNase A and 0.8 mg/mL
proteinase K for 1-2 hours at 50°C and then mixed with 50 µ L NaI
solution (7.6 M NaI, 20 mM EDTA-2Na, 40 mM Tris-HCl; pH 8.0),
and then 200 µ L of ethanol. After centrifugation for 20 minutes at
20,000 xg, the precipitate was washed with 1 mL of 70% ethanol and
dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA; pH 8.0).
Sample (10-20 µ L) was subjected to 2% agarose gel electrophoresis
in TBE buffer (89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA-
2Na). DNA molecular marker (Bayou Biolabs, Harahan, LA, USA)
and DNA from apoptotic HL-60 cells induced by 1 µ g/mL
actinomycin D (Act D) were run in parallel (32). After staining with
ethidium bromide, DNA was visualized by UV irradiation and
photographed by a CCD camera (Bio Doc-Ic; UVP, Inc., Upland,
CA, USA).
Assay for caspase activation. Cells were washed with PBS(–) and
lysed in lysis buffer [50 mM Tris-HCl (pH7.5) 0.3% NP-40, 1 mM
DTT]. After standing for 10 minutes on ice and centrifugation for 5
minutes at 10,000 xg, the supernatant was collected. Lysate (50 µ L,
equivalent to 200 µ g protein) was mixed with 50 µ L of the lysis
buffer containing substrates for caspase-3 (DEVD-p-nitroanilide
(pNA)), caspase-8 (IETD-pNA) or caspase-9 (LEHD-pNA)
(Kamiya Biochem Co., Seattle, WA, USA). After incubation for 2
hours at 37°C, the absorbance at 405 nm of the liberated
chromophore pNA was measured by a plate reader (32).
Detection of acidic vesicular organelles with acridine orange staining.
Acidic vesicular organelles were stained with acridine orange
(Sigma Chemical Co., St. Louis, MO, USA) as described
elsewhere (32). HSC-4 cells were stained with 1 µ g/mL acridine
orange for 15 minutes. Samples were then examined under a Laser
Scanning Microscope LSM510 (Carl Zeiss Inc., Gottingen,
Germany), using the following filters: excitation 488 nm, emission
505-530 nm and >650 nm.
Electron microscopy. Cells were harvested by 0.25% trypsin-
0.025%EDTA in PBS(–), and pelleted by centrifugation at 1,000
rpm for 5 minutes. The cells were fixed for 1 hour with 2%
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) at 4°C,
postfixed for 1 hour with 1% osmium tetraoxide-0.1 M cacodylate
buffer (pH 7.4) at 4°C, dehydrated, then embedded in Araldite 502
(CIBA-GEIGY, Basel, Switzerland). Fine sections were stained
with uranyl acetate and lead citrate, and then observed under a
JEM-1210 electron microscope (JEOL, Tokyo, Japan) at an
accelerating voltage of 100 kV (32).
Results
Structure and activity relationship. Benzo[b]cyclohepta[e]
[1,4]thiazine [1] showed very weak cytotoxic activity against
both normal and tumor cells (CC50>500 µ M), yielding
essentially no tumor-specific cytotoxicity (TS=1.3) (Table
II). The introduction of two bromines at the C-6 and -8
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Figure 1. Structures of the 26 benzocycloheptoxazines studied.
positions of the cycloheptane ring [2] considerably
enhanced cytotoxicity against both normal and tumor cells,
and therefore did not increase the tumor-specificity
(TS=0.8). The introduction of three bromines at the C-6, -
8, and -10 positions of the cycloheptane ring [3], enhanced
the cytotoxicity against tumor cells to a greater extent,
enhancing the tumor-specificity (TS=5.6).
6H-Benzo[b]cyclohepta[e][1,4]diazine [4] had higher
cytotoxicity than benzo[b]cyclohepta[e][1,4]thiazine [1] and
expressed some tumor-specificity (TS=3.7). The 6H-
bnzo[b]cyclohepta[e][1,4]diazine cation [5] essentially had no
cytotoxicity against normal or tumor cells (CC50>500 µ M)
and had low tumor-specificity (TS=1.1).
Benzo[b]cyclohepta[e][1,4]oxazine [6] showed weak
cytoxicity and tumor-specificity (TS=1.7). The introduction
of one bromine at C-6 of the cycloheptane ring [7]
significantly enhanced the cytotoxicity, but but not
particularly increase the tumor-specificity (TS=2.6). The
introduction of two bromines at C-6 and -8 of the
cycloheptane ring [8] did not increase either cytotoxicity or
tumor-specificity (TS=1.7). It should be noted that the
introduction of three bromines at C-6, -8, and -10 of the
cycloheptane ring [9] selectively enhanced the cytotoxicity
against tumor cells, significantly enhancing the tumor-
specificity (TS=12.5). However, the introduction of only
one bromine at C-7 [11], -8 [10] or -9 of the cycloheptane
ring [12] slightly enhanced the cytotoxicity, but did not
particularly increase the tumor-specificity (TS=2.2, 2.9 and
1.6, respectively). The introduction of an isopropyl group at
C-8 [13] or -9 of the cycloheptane ring [14] slightly
enhanced the tumor-specificity (TS=6.2 and 2.5,
respectively). The introduction of an acetoxy group at C-6
[15], -8 [16] or -9 [18], or that of bromine at C-8 and an
acetoxy group at C-6 [17] slightly enhanced the tumor-
specificity (TS=4.0, 1.8, 2.6 and 4.6, respectively). The
introduction of a methyl group at C-2 of the benzene ring
[19] marginally enhanced the tumor-specificity (TS=2.4). It
should be noted that the introduction of bromine at C-6 and
a methyl group at C-2 [20], or that of bromine at C-6 and
chlorine at C-2 [21] greatly enhanced the tumor-specificity
(TS=9.1 and 11.5, respectively). On the other hand, the
introduction of bromine at C-8 and a methyl group at C-2
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Figure 2. Effect of three benzocycloheptoxazine derivatives [9, 20, 21] on the induction of DNA fragmentation in three human tumor cell lines. HSC-2
(left), HSC-4 (center) and HL-60 cells (right) were incubated for 6 (upper panel) or 24 hours (lower panel) with the indicated concentrations (µM) of
[9], [20] or [21]. DNA was then extracted and submitted to agarose gel electrophoresis. Marker DNA and DNA from apoptotic HL-60 cells induced by
UV irradiation were also run. Representative data from one of three independent experiments are shown.
[22], and that of bromine at C-8 and chlorine at C-2 [23]
only slightly enhanced the tumor-specificity (TS=2.1 and
3.9, respectively).
14H-[1,4]Benzoxazino[3',2':3,4]cyclohepta[1,2-b][1,4]
benzoxazine [24] and its 7-bromo- [25] and 7-isopropyl-
[26] derivatives had much lower cytotoxicity and tumor-
specificity (TS=1.1, 1.6 and 1.3, respectively) (Table I).
Drug sensitivity of cell lines. Among the four tumor cell lines,
HL-60 cells were generally the most sensitive, followed by
HSC-2 cells. HSC-3 and HSC-4 cells were the most resistant.
Type of cell death induced. We next investigated the type of
cell death induced by the most tumor-selective compounds
[9, 20, 21]. When HL-60 cells were incubated with any of
these compounds near their CC50, internucleosomal DNA
fragmentation, a biochemical hallmark of apoptosis, was not
observed at 6 hours after treatment, but it became
detectable at 24 hours after the treatment (Figure 2). These
compounds also induced DNA fragmentation in HSC-2
cells, at the concentration of CC50, whereas they failed to
induce DNA fragmentation in HSC-4 cells (Figure 2).
Compounds [9, 20, 21] when used near the CC50 also
activated caspase-3, caspase-8 and caspase-9 in HL-60 cells.
They also activated these caspases in HSC-2 cells, but only
at concentrations higher than the CC50, whereas they failed
to activate caspases in HSC-4 cells (Figure 3).
Compounds [9, 20, 21] induced the formation of acidic
organelles easily recognizable as red dot-like structures after
staining with acridine orange (Figure 4). To confirm the
occurrence of autophagy, we investigated the changes of the
fine cell structure on treatment with these compounds by
transmission electron microscopy (Figure 5). When HSC-2
cells were cultured by compound [9] at the CC50 (29 µ M),
moderate enlargement of mitochondria and the endoplasmic
reticulum was observed (Figure 5B). When HSC-2 cells were
cultured with compound [9] at a concentration twice or
quadruplicate that of the CC50 (57 or 114 µ M), the
enlargement of the endoplasmic reticulum was more evident
(Figure 5C, D) than that observed at CC50 (29 µ M), providing
the vacuole-like profiles. The nuclear membrane was also
enlarged in places (Figure 5C, D). Findings similar to these
found with compound [9] were observed in the cells cultured
with compound [20] (Figure 5E, F). The cells cultured with
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Figure 3. Effect of three benzocycloheptoxazine derivatives [9, 20, 21] on caspase activation in three human tumor cell lines. HSC-2 (left), HSC-4
(center) and HL-60 cells (right) were incubated for 6 hours with the indicated concentrations of [9], [20] or [21] or 1 µg/mL actinomycin D (Act-D)
(positive control). Each point represents the mean±S.D. from 3-4 independent experiments.
compound [21] showed no evident changes at the CC50 (25
µ M) or at twice the CC50 (50 µ M) (Figure 5G, H). However,
at four times the CC50 (100 µ M), the vacuolation of the
endoplasmic reticulum and the presence of a number of
lamellar body-like organelles were found (Figure 5H, I).
Discussion
The present study demonstrates that parent compounds such
as benzo[b]cyclohepta[e][1,4]thiazine [1], benzo[b]
cyclohepta[e][1,4]oxazine [6] and 14H-[1,4]benzoxazino
[3',2':3,4]cyclohepta[1,2-b][1,4]benzoxazine [24] alone had
very weak cytotoxicity and tumor-specificity. The introduction
of three bromines to the cycloheptane ring of compounds [1]
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Figure 4. Effect of benzocycloheptoxazine derivatives [9, 20, 21] on the cytoplasmic dsistribution of acridine orange. HSC-2 cells were incubated for 6
hours with the indicated concentrations of [9], [20] or [21]. Excitation filter 488 nm, emission filter 505-530 nm (green) and >650 nm (red).
and [6] significantly enhanced their cytotoxicity against
tumor cells, elevating the tumor-specificity index (TS=5.6,
12.5). The introduction of one bromine at C-6 of the
cycloheptane ring [7] slightly increased the tumor-specific
index (TS=2.6), but the introdution of bromine together with
a methyl group [20] or chlorine [21] at C-2 of the benzene
ring significantly enhanced the tumor-specificity (TS=9.1 and
11.5, respectively).
The present study also demonstrated that the most
tumor-selective compounds [9, 20, 21] induced apoptotic
cell death to various extents in the three tumor cell lines.
By treatment with any of these compounds, HL-60 cells
were committed to apoptotic cell death. On the other
hand, HSC-2 cells were committed to autophagic cell
death at lower concentrations and apoptotic cell death at
higher concentrations, suggesting the interconvertibility
between autophagy and apoptosis, depending on the
concentration. This is consistent with recent reports that
inhibitors of autophagy stimulated cell death toward
apoptosis (32, 33).
We recently reported that 1-trichloroacetyl-3-bromo-2-
methoxyazulene and 1-trichloroacetyl-3-chloro-2-ethoxya-
zulene induced apoptotic cell death in HL-60 cells, whereas
they induced autophagic cell death in HSC-4 cells (34).
Since HSC-4 cells are much more resistant to these
compounds, the induction of autophagic cell death may be
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Figure 5. Electron microscopy of control and dying HSC-2 cells. HSC-2 cells were incubated for 4 hours without treatment (control) (A) or with [9] at 29
(B), 57 (C) or 114 µM (D), [20] at 16 (E) or 66 µM (F), or [21] at 25 (G), 50 (H) or 100 µM (I) and then processed for electron microscopy. Bar: 1 µm.
related to the extent of drug resistance. This is supported by
the fact that malignant brain tumor cell lines, which are
resistant to many anticancer drugs, have been reported to
undergo autophagy (35, 36).
In conclusion, we found that benzocycloheptoxazines
derivatives induced different types of cell death depending
on the type of cells and on the concentration used. Further
study is required to clarify the mechanism by which such
diversity is produced.
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